Lupin builds ophthalmology platform as presbyopia drops seek to challenge reading glasses
Through VISUfarma’s rights to FDA-approved Yuvezzi, Lupin is expanding in prescription eye care. The near-vision drop points to a potential recurring-use category alongside reading glasses, with the global presbyopia market projected to reach $13.88 billion by 2030.
What happened
Lupin is expanding its European ophthalmology platform through VISUfarma’s rights to Yuvezzi, a presbyopia eye drop. India already has Entod’s PresVu,
Key facts
- Yuvezzi may improve near vision for up to 8 hours
- Yuvezzi received US FDA approval in January 2026 and launched in the US in March 2026
- Lupin acquired VISUfarma in April 2026
- VISUfarma portfolio includes more than 60 branded ophthalmology products
- Global presbyopia market estimated at $10.66 billion in 2025 and projected at $13.88 billion by 2030
What changed
Lupin is expanding its European ophthalmology platform through VISUfarma’s rights to Yuvezzi, a presbyopia eye drop. India already has Entod’s PresVu, indicating a potential recurring-use prescription category that could complement rather than replace reading glasses.
Why this matters
Lupin’s VISUfarma platform gives pharmacy and eye-care operators a new prescription-led presbyopia category that could complement, rather than immediately replace, reading-glasses sales.
What to watch
- Yuvezzi launch timing, market-access status and reimbursed versus cash-pay pricing by European country.
- Prescription volume, refill rates and discontinuation data during the first 12 to 24 months of commercialization.
- Ophthalmologist versus optometrist prescribing adoption and the scale of direct-to-consumer patient demand.
- Competitive launches of presbyopia drops, including products with longer duration, better tolerability or more favorable pricing.
- VISUfarma revenue growth, sales-force retention and evidence of cross-selling across Lupin's specialty portfolio.